MedTrace Logo

Combination of Cryosurgery and NK Immunotherapy for Advanced Kidney Cancer

NCT02843607 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2019-09-12

No results posted yet for this study

Summary

The aim of this study is the safety and efficacy of cryosurgery plus NK immunotherapy to advanced kidney cancer.

Conditions

  • Metastatic Renal Cell Cancer

Interventions

DEVICE

Cryosurgery

Argon-helium cryosurgical system (percutaneous ablation under CT or ultrasound guidance)

BIOLOGICAL

NK immunotherapy

Natural killer cell (each treatment: about 10 billion cells transfusion in 3 times, i.v.)

Sponsors & Collaborators

  • Shenzhen Hank Bioengineering Institute

    collaborator OTHER

  • Fuda Cancer Hospital, Guangzhou

    lead OTHER

Principal Investigators

  • Guifeng Liu, PhD · Fuda Cancer Hospital, Guangzhou

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-07-01
Primary Completion
2017-07-01
Completion
2019-07-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02843607 on ClinicalTrials.gov